Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Increasingly Seems Focused On Combo Therapy In NASH

Apr 12 2019

• By Joseph Haas

Dr Analyzing Liquid

Related Content

In NASH, Gilead Swung For The Fences And Struck Out Again

Feb 12 2019

Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III

Feb 11 2019

Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Apr 11 2019

NASH Pipeline: Racing To The Finish

Mar 21 2019

Gilead Faces Challenges In HCV, But Competitors Would Switch Places

Feb 12 2016

Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Apr 20 2018

Related Companies

Gilead Sciences, Inc.

Novo Nordisk A/S

Pharmasset, Inc.

Intercept Pharmaceuticals, Inc.

Additional Topics

Commercial Clinical Trials Deals Liver & Hepatic BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window